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Although intraatrial reentry has been traditionally listed as
a mechanism for supraventricular tachycardia, few reports
describing the clinical features of this arrhythmia exist.
Nineteen patients with a clinical history of sustained su-
praventricular tachycardia were diagnosed as having in-
traatrial reentrant tachycardia. Seventeen (89%) patients
of the 19 had underlying structural heart disease and 17
had echocardiographic evidence of atrial enlargement; the
mean left ventricular ejection fraction was 51 ± 16%. A
history of concomitant atrial fibrillation or flutter was
present in 13 patients (68 %). The mean atrial cycle length
during tachycardia was 326 ± 57 ms (range 260 to 460).
Fourteen patients had 1:1 atrioventricular (AV) conduction
during tachycardia, of whom 50% had an RP'/RR' ratio
>0.5.
Intravenous adenosine (dose range 37.5 to 150 p,g/kg)
and verapamil (dose range 5 to 10 mg) had no effect on
atrial tachycardia cycle length in 13 of 14 and 9 of 9
patients, respectively, despite induction of second degree
Within the last decade, there have been significant advances
in understanding the mechanisms and pharmacologic treat-
ment of the common forms of supraventricular tachycardia.
However, experience with less common arrhythmias, par-
ticularly tachycardias due to intraatrial reentry, has been
limited. Intraatrial reentry has been considered as the prob-
able mechanism for tachycardia that has a regular atrial
rhythm, is initiated and terminated by programmed stimula-
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AV block. Type la antiarrhythmic drugs achieved long-
term suppression of intraatrial reentrant tachycardia in
only 6 patients, whereas amiodarone (326 ± 145 mg/day)
was successful in 11 patients during a 32 ± 20 month
follow-up period. The remaining two patients and one
patient who later developed amiodarone· toxicity either
progressed to (n =1) or had (n =2) catheter-induced high
grade AV block and were treated with long-term ventricu-
lar pacing.
It is concluded that intraatrial reentrant tachycardia is
often associated with structural heart disease, particularly
of types that cause atrial abnormalities, but left ventricular
dysfunction is not a requisite finding. Other arrhythmias
are frequently observed in these patients. This arrhythmia
responds poorly to type la antiarrhythmic drugs, but is
effectively treated with amiodarone. Catheter ablation of
the AVjunction offers a therapeutic option for patients who
are refractory to medical therapy.
(J Am Coli CardioI1990;15:1345-54)
tion and has an atrial activation sequence that differs from
that of normal sinus rhythm (1). Unlike the more common
forms of supraventricular tachycardia, this arrhythmia
does not require atrioventricular (AV) node participation
in the reentrant circuit and can persist despite induction of
high grade AV node block (2). The primary electrocardio-
graphic (ECG) feature that has been used to differentiate
intraatrial reentrant tachycardia from atrial flutter is its
slower rate (3).
There have been only sporadic clinical reports (l,4-6)
describing patients with intraatrial reentrant tachycardia,
and the electrophysiologic characteristics and results of
long-term therapy of this arrhythmia are poorly character-
ized. In the present study, we evaluated 19 patients with
sustained intraatrial reentrant tachycardia. Our purpose is to
report salient clinical, ECG and electrophysiologic charac-
teristics of these patients and review their response to
antiarrhythmic therapy.
0735-1097/90/$3.50
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Table 1. Clinical Features of 19 Patients With Intraatrial Reentrant Tachycardia
Age (yr)1 Symptom Duration Prior AAD Cardiac Atrial Concomitant
Pt. No. Gender (mo) Trials Disease Enlargement LVEF Arrhythmias
I 311M 3 0 Congenital Yes 60 AFib, AFlut, VT
2 41/M 9 0, A, Pr, P CAD 75 AFlut
3 53/F I 0, P, Q Valvular Yes 47 AFib, AFlut
4 74/M 3 P CAD VT
5 47/M 7 V, Q, Pr CM No 55 AFib, AFlut
6 761M 3 D,V,Q,Mx CM Yes 23 AFib, AFlut, AVNR, VT
7 261M 27 V,P, T,Q Valvular No 52 VT
8 62/F 12 D,Q Valvular Yes 35 AFib, AFlut
9 161M 120 0, P, Q Congenital Yes 71 SB
10 46/M <I D,P None Yes 60 AFib, VT
II 191M 27 D,Dp Congenital Yes 73 AFib, VT
12 62/F 4 0, Dz, Pi, Pr, Q None No 60 AFlut
13 71/F <I 0, Pr CAD Yes 40 AFlut
14 331M I D,Q CM Yes 12 VT
15 68/F I 0, V, Pr CAD No 33 AFib
16 381M I Valvular Yes 48 None
17 79/F I CM Yes 52 AFib, AFlut
18 121M I Pr CAD Yes 30 None
19 76/F 12 0, V, P, Pr Valvular Yes 60 AFlut
A =atenolol; AAD = antiarrhythmic drugs; AFib = atrial fibrillation; AFlut =atrial flutter; AVNR =atrioventricular node reentry; CAD = coronary artery
disease; CM = cardiomyopathy; 0 = digoxin; Dp = diphenylhydantoin; Dz = diltiazem; F = female; LVEF = left ventricular ejection fraction; M = male;
Mx = mexiletine; P = propranolol; Pi = pindolol; Pr = procainamide; PI. = patient; Q = quinidine; SB = sinus bradycardia; T = timolol, V = verapamil;
VT = ventricular tachycardia.
Methods
Study patients. Nineteen patients who had a history of
recurrent episodes of symptomatic tachycardia that met
criteria for intraatrial reentry were evaluated at the Univer-
sity of Virginia Hospital between September 1982 and Sep-
tember 1987. In this study, the criteria used for definition of
the tachycardia were similar to those proposed by Josephson
and Seides (3) and included: 1) an atrial cycle length >250 ms
and <600 ms in the absence of antiarrhythmic medication; 2)
a P wave morphology or an atrial activation sequence, or
both, distinctly different from that documented during sinus
rhythm; 3) persistence of the atrial arrhythmia despite spon-
taneous or pharmacologically induced high grade AV node
block; and 4) initiation or termination, or both, with appro-
priately timed atrial extrastimuli or rapid atrial pacing, All
patients had presented with one or more clinical episodes of
tachycardia, with a duration of 2':: 1h that required interven-
tion for termination. Ongoing tachycardia was defined as
tachycardia that was continuous from the initial symptomatic
presentation until termination at the time of invasive evalua-
tion. All studies were performed for clinical indications, and
all patients gave informed consent before invasive testing.
Cardiac evaluation included cardiac catheterization with
coronary angiography in 8 patients and two-dimensional
echocardiography in 17 patients. Atrial enlargement was
defined according to standard echocardiographic criteria as a
left atrial dimension >4 cm in the parasternal plane. Left
ventricular ejection fraction was calculated from biplane
cineangiograms according to standard methods (8 patients) or
by a visual estimate from two-dimensional echocardiograms
by two observers when an angiogram was not available (10
patients).
Electrophysiologic study. Studies were performed with
the patient in a fasting nonsedated state after written in-
formed consent had been obtained. Antiarrhythmic drugs
were discontinued 2'::48 h before the study. Patients under-
went evaluation with a single (6 patients) or multiple (13
patients) 6F quadripolar electrode catheters according to
standard electrophysiologic procedures, as previously de-
scribed (7). During an episode of sustained tachycardia,
bipolar atrial electrograms were recorded at a paper speed of
200 mm/s. The atrial catheter was positioned at four to six
sites around the tricuspid valve ring, at high, mid and low
sites on the anterior, lateral and septal walls, in the left
atrium if a probe-patent foramen ovale was present and in
the coronary sinus in selected cases. Relative atrial activa-
tion times were measured from the earliest onset of the P
wave on the surface EeG to the first rapid deflection of the
atrial electrogram across the baseline. The earliest site of
atrial activation was defined as the earliest presystolic atrial
activity that occurred in the latter half of the atrial cycle.
Tachycardia cycle length was determined by measuring the
AN interval from intracardiac electrograms acquired during
ongoing clinical tachycardia over 30 s. In cases where
additional episodes of atrial tachycardia with different rates
occurred in the clinical setting, their cycle length was
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Figure 1. Patient 19. Twelve lead sur-
face electrocardiograms during normal
sinus rhythm (upper three panels) and
intraatrial reentrant tachycardia (lower .: L,:
three panels). L
I i.J .L._
I . I I
I . ' J
I' .!
I:
approximated by measurement of the PP intervals on a
surface EeG at a paper speed of 25 mm/s.
Pharmacologic testing. Adenosine (37.5 to 150 jlg/kg) was
administered as a rapid bolus injection to 13 patients accord-
ing to a protocol previously reported (2). If AV block was
not achieved at the initial dose, the dose was increased
incrementally until transient AV block was observed. Addi-
tional intravenous acute pharmacologic testing was per-
formed with verapamil (2.5 to 10 mg; nine patients), propran-
olol (0.1 mg/kg, one patient) and procainamide (500 to 1,500
mg, five patients).
Long-term therapy and follow-up. All patients underwent
therapeutic trials with a type la antiarrhythmic agent (quin-
idine, procainamide or disopyramide) alone or in combina-
tion with digoxin or a beta-adrenergic blocker, or both.
Therapy was discontinued if the patient experienced in-
tolerable side effects or if episodes of tachycardia recurred
clinically despite therapeutic antiarrhythmic drug levels. If
therapy with these agents was unsuccessful, patients were
then treated with amiodarone, 200 to 400 mg/day after a 4 to
7 day loading period of 800 mg/day. Two patients underwent























Figure 2. Patient 18. Surface electrocardiographic leads I, II and III
during sustained intraatrial reentrant tachycardia (cycle length 290
ms) with I: I atrioventricular (AV) conduction (panel A) and after an
intravenous injection of 10 mg of verapamil (panel B). This tracing has
a superficial appearance of normal sinus rhythm, but careful inspec-
tion reveals persisting atrial tachycardia with 2: I AV block. After
intravenous administration of 1.0 g of procainamide (panel C), the
patient's rhythm converted spontaneously to sinus rhythm and dem-
onstrated a change in Pwave configuration and axis (best seen in lead
III), consistent with a change in intraatrial activation sequence.
darone therapy to control their arrhythmia. All patients were
followed up after their initial evaluation at regular intervals
to assess continuing safety and efficacy of therapy. Patient
follow-up data were obtained through personal office visits
or telephone contact with the referring physician, or both.
Results
Clinical and ECG data (Table 1). The mean age of the 19
patients was 52 ± 21 years. There was a wide range of
duration of antecedent symptoms (2 weeks to 10 years). All
patients were symptomatic during tachycardia and had re-
ceived a mean of 2.5 ± 1.5 prior antiarrhythmic drug trials
without success. Structural heart disease was a common
finding, being observed in 17 (89%) of the 19 patients. Of the
five patients with valvular heart disease, four had mitral and
one had aortic disease. The three patients with congenital
heart disease had tetralogy of Fallot (two patients) and an
atrial and ventricular septal defect (one patient). Left atrial
enlargement was common. Left ventricular ejection fraction
at rest was depressed «60%) in 11 of 18 patients (mean 51 ±
16%), but only 5 patients demonstrated severe impairment of
systolic function with an ejection fraction <40%.
Fourteen patients had a history of other electrocardio-
graphically discrete atrial arrhythmias in addition to intra-
atrial reentry. Four patients demonstrated episodes of spon-
taneous sustained monomorphic ventricular tachycardia
(lasting>30 s or requiring cardioversion), and three patients
had nonsustained ventricular tachycardia. Other arrhyth-
mias observed included AV node reentrant tachycardia and
intermittent sinus arrest with junctional bradycardia. Only
two patients had intraatrial reentrant tachycardia as their
only documented rhythm abnormality.
A normal P wave axis (0° to +90°) was observed in 16
patients during sinus rhythm and in 10 patients during
intraatrial reentrant tachycardia. In all patients (except one
in whom a sinus mechanism was never identified), the P
wave axis or configuration was clearly different during the
two separate rhythms (Fig. I). The mean P wave axis shift
(positive or negative) was 87 ± 61° (range 15 to 165).
Although some patients always manifested second degree
AV block during tachycardia, 14 of the 19 patients had 1: I
AV conduction during atrial tachycardia at some point
during their clinical course (Fig. 2). The RP'/RR' ratio during
episodes of tachycardia with 1: 1 AV conduction was vari-
able, ranging from 0.2 to 0.7. and was >0.5 in 7 of the 13
patients with discernible P waves during tachycardia.
Electrophysiologic data (Table 2). The mean tachycardia
cycle length observed in the absence of drug therapy at
electrophysiologic study was 326 ± 57 ms (range 260 to 460).
All tachycardias showed minor beat to beat variability in
cycle length (5 to 15 ms). Two patients demonstrated a fixed
pattern of cycle length oscillation during episodes of tachy-
cardia. Eight patients had only one morphologic intraatrial
tachycardia documented, but 11 patients demonstrated ei-





Table 2. Electrocardiographic and Electrophysiologic Characteristics of 19 Patients
P Wave Axis RP'fRR' Earliest Site
IARTCL CL Shift Maximal Observed During I: I of Atrial
Pt. No. (ms) Oscillation NSRto IART AV Conduction Conduction Activation
I 260 No +155 ):) 0.54 NA
2 270,370 No +30 1:1 0.43 Mid Jat RA
3 315,400 No +180 ):1 0.40 Low lat RA
4 275,310 No +90 1:1 High lat RA
5 305 No -150 1:1 0.51 Mid LA
6 340. 350. 395 No -60 1:1 0.41 NA
7 320. 360. 460 Yes -15 1:1 0.22 Mid lat RA
8 300 No -30 2:1 High lat RA
9 260 No -120 2:1 NA
10 300 Yes +30 1:1 0.33 NA
II 280,315 No -60 1:1 0.57 NA
12 380,460 No -120 1:1 0.70 Low post RA
13 280,300 No +15 2:1 Mid lat RA
14 280 No -150 2:1 Low ant RA
15 280,345.460 No -165 1:1 0.65 Low sept RA
16 380.440 No +15 J:) 0.58 Low lat RA
17 350 No NAt 2:1 Low sept RA
18 290,325 No -30 1:1 0.50 Low lat RA
19 430. 380. 305 No +150 1:1 0.40 Mid lat RA
'Onset of P wave not discernible in the available rhythm strip during intraatrial recurrent tachycardia (IARTl and I: I atrioventricular (AV) conduction; tAxis
of P wave during intraatrial reentrant tachycardia indeterminate. ant = anterior; CL = cycle length; LA = left atrium; lat = lateral; NA = not available:
NSR = normal sinus rhythm: post = posterior; RA = right atrium; sept = septal: other abbreviations as in Table I.
ther two or three tachycardias with different cycle length. P
wave configuration or atrial activation sequences (Fig. 3).
Eleven patients manifested ongoing atrial tachycardia at
the time of invasive evaluation. In seven of these patients.
initiation of the tachycardia by programmed stimulation was
not demonstrated after its successful termination because
attempts at reinitiation either yielded atrial fibrillation or
atrial flutter or the clinician's judgment was against attempt-
ing reinitiation of the tachycardia. Tachycardia in the re-
maining patients could be reproducibly initiated with single.
double or triple atrial premature stimuli (four, three and two
patients, respectively) or with rapid atrial pacing (three
patients) (Fig. 4 and 5). In the four patients whose tachycar-
dia was initiated by single atrial extrastimuli, a critical
intraatrial conduction delay was not measurable coincident
with tachycardia onset. Tachycardia in all patients could be
terminated by rapid atrial pacing. although addition of a type
la drug to facilitate paced termination was required in five
patients. Single or double atrial extrastimuli were not effec-
tive in terminating the arrhythmia in any patient.
Mapping ofmultiple right atrial and coronary sinus sites
was performed in 14 patients to determine the relative atrial
activation sequence (Fig. 6). Presystolic atrial activity was
recorded in the right atrium in 13 of the 14 patients. Only one
patient demonstrated atrial presystolic activity from a left
atrial location.
Acute drug testing. During tachycardia. intravenous
adenosine was administered to 14 patients in incremental
doses until a transient period of second or third degree AV
block was observed (mean 99 ± 38/Lg/kg. range 37.5 to 150).
Despite the induction of high grade AV block in all patients.
no tachycardia was terminated and there was no effect on
atrial cycle length in 13 patients. In one patient atrial
tachycardia converted to atrial flutter after adenosine admin-
istration and, hence. the effect of the drug on intraatrial
reentrant tachycardia cycle length could not be assessed.
Intravenous verapamil (5 to 10 mg) was administered to nine
patients during sustained atrial tachycardia; it did not termi-
nate tachycardia or alter atrial cycle length in any patient
despite increasing the degree of AV block (Fig. 7).
Long-term therapy and follow-up (Table 3). Patients un-
derwent 2.5 ± 1.5 unsuccessful therapeutic trials with vari-
ous drugs including digoxin, verapamil, a beta-blocker and
type la antiarrhythmic agents. Drugs that increased AV
node refractoriness often resulted in immediate symptomatic
improvement as a result of a decrease in ventricular re-
sponse during the arrhythmia. However, these drugs did not
prevent recurrence of intraatrial reentry or alter the tachy-
cardia cycle length, and stable long-term rate control was not
achieved.
The final discharge drug regimen was chosen on clinical
grounds without repeat programmed stimulation, and pa-
tients were followed up for symptomatic clinical recurrence.
In 11 patients one or more type la antiarrhythmic agents
were unsuccessful clinically. and these patients were even-
tually treated with amiodarone at a dose of 326 ± 145 mg/day
1350 HAINES AND DIMARCO
INTRAATRIAL REENTRANT TACHYCARDIA












A A 380 I
HRA -:i",A-M~~~~W-/i ~~~\-J~~\-
r I (v t I i I "' (
I A A'~ •• I·~ r· I .~ ~
HB ~.rr".;~.r.~.~ .. ,~.!Y'~.!Y·'''./~.~.r
c.
Figure 3. Surface electrocardiographic (ECG)
leads I, aVF and VI and intracardiac electro-
grams from the high right atrium (HRA) and the
region of the His bundle (HB). The vertical line
represents the onset of the surface ECG P wave.
Panel Ashows normal sinus rhythm and a normal
atrial activation sequence with the high right
atrial electrogram onset coincident with the P
wave onset. Panel B demonstrates intraatrial re-
entrant tachycardia with a cycle length of 380 ms.
The atrial activation sequence is different from
that seen during sinus rhythm. Panel C demon-
strates another intraatrial reentrant tachycardia
in the same patient, with a 460 ms cycle length
and another unique atrial activation sequence.
Electrograms have been retouched.
aVF
~1 sec--i
(range 100 to 600) after an appropriate loading period. Six
patients were treated chronically with a type la agent alone
or in combination with digoxin or a beta-blocker. The
remaining two patients had high grade AV block that devel-
oped spontaneously or was induced with transcatheter elec-
trical ablation of the His bundle. and were treated with
permanent ventricular pacing.
During a follow-up period of32 ± 20 months (range 3 to
65), all but two patients had successful suppression of their
intraatrjaJ reentrant tachycardia. One patient stopped taking
procainamide and continues to have recurrent symptomatic
atrial tachycardia despite therapy with digoxin and pindolol.
The second patient had a favorable initial response to
amiodarone (400 mg/day), but developed amiodarone pulmo-
nary toxicity; she has since undergone successful transcath-
eter electrical His bundle ablation. Despite good control of
their atrial arrhythmias, nine patients died during the follow-
up period. Causes of death included congestive heart failure
(two patients), pulmonary embolism (one patient), intract-
able ventricular tachycardia (one patient) and noncardiac
disease (five patients).
Discussion
Although intraatrial reentry has been accepted as one of
several mechanisms potentially responsible for recI:irrent
supraventricular tachycardia, few reports (l ,4-6,8) describ-
ing the clinical and the electrophysiologic characteristics of
patients with this arrhythmia are available. The observations
contained in the present study document that supraventric-
ular tachycardia due to intraatrial reentry is a distinct
syndrome and that an understanding of the mechanism of











this arrhythmia, as previously defined, is necessary for
optimal clinical management of these patients.
Clinical features. The EeG features of the tachycardias
in the patients in this series are distinctive and usually allow
the arrhythmias to be differentiated from the other more
common forms of paroxysmal supraventricular tachycardia.
Figure 4. Patient 13. Surface electrocardiographic leads I and VI
and intracardiac electrograms from the high right atrium (HRA) and
the region of the His bundle (HB). Panel Ademonstrates initiation of
sustained intraatrial reentrant tachycardia with triple atrial extra-
stimuli. Note the minor degree of cycle length variability. Panel B
demonstrates termination of the atrial tachycardia by a burst of
rapid atrial pacing (S). E1ectrograms have been retouched.
Figure 5. Surface electrocardiographic leads I, aVF
and VI and intracardiac electrograms from the high
right atrium (HRA) and the low posteromedial right
atrium (PMA) during intraatrial tachycardia with a 280
ms cycle length. The upper panel demonstrates onset
of rapid atrial pacing (S) at a cycle length of 260 ms
from the high right atrial catheter. The continuation in
the lower panel shows cessation of the paced drive
with fractionated local electrical activity (A'A) mea-
sured from the low posteromedial right atrial elec-
trode, The return cycle length of the low posterome-
dial right atrial electrogram (260 ms) is identical to the
pacing cycle length, thus demonstrating one criterion
for entrainment.
1----1 sec----l
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Figure 6. Catheter map of selected right atrial sites during sustained
intraatrial reentrant tachycardia. Top to bottom, the tracings repre-
sent surface electrocardiographic (ECG) leads I, aVF and VI and
right atrial electrograms from the region of the His bundle (HB),
anterior (Ant), anterolateral (Ant Lat), lateral (Lat), posterior (Post)
and posteromedial (P Med) segments. The vertical line represents
the onset of the P wave on the surface ECG. Electrograms have
been retouched.
The most helpful finding for localizing the arrhythmia origin
was the documentation of second degree AV block during
sustained tachycardia. This finding either occurred sponta-
neously or could be induced by pharmacologic agents or
physiologic maneuvers during the tachycardia. Other ECG
findings were less helpful; RP' intervals were variable and no
characteristic P wave configuration pertained to all patients.
Several patients manifested more than one P wave config-
uration during different episodes of tachycardia.
In many cases, the recognition of sustained tachycardia
with AV block led to an initial clinical diagnosis of "parox-
ysmal atrial tachycardia with block" due to digoxin toxicity.
Although, historically, atrial tachycardia with block has
often been thought to be a specific marker for digitalis
toxicity (9,10), the arrhythmias in this series were not
clinically improved after withdrawal of digoxin and could
usually be reinitiated by stimulation in the total absence of
cardiac glycosides. Despite the perception that digitalis
toxicity accounts for the majority of cases of atrial tachycar-
dia with block (11), intraatrial reentry is more prevalent in
our referral center.
Other clinical features served to differentiate intraatrial
reentrant tachycardia from other forms of paroxysmal su-
praventricular tachycardia. Our patients frequently had clin-
ically significant structural heart disease, and 17 of the 19
patients had concomitant arrhythmias associated with con-
duction abnormalities within atrial or ventricular myocar-
dium. The high mortality rate in this group of patients during
the follow-up period underscores their poor overall cardiac
and medical condition. As ·in patients with recurrent sus-
tained ventricular arrhythmias in the setting of structural
abnormalities of the ventricular myocardium, it appears that
our patients frequently had the potential for several different
morphologically distinct atrial arrhythmias as a result of
large areas of electrically abnormal atrial tissue.
Previous studies. Previous reports (1,5,6,8) of patients
with intraatrial reentrant tachycardia have been limited by
small numbers of patients, with limited or no follow-up data
reported. Coumel et al. (4) reported 20 cases of intraatrial
reentrant tachycardia, but the majority of their patients had
no apparent documentation of this arrhythmia outside the
setting of invasive electrophysiologic testing; the patients
were young and had no structural heart disease. The clinical
and electrophysiologic characteristics of the patients in our
series are similar to those observed in patients with related
rhythm disorders. Like patients with clinical sustained atrial
flutter, patients with intraatrial reentrant tachycardia had a
high prevalence of underlying structural heart disease, and
their tachycardia could be initiated and terminated by appro-
priate atrial extrastimuli or overdrive pacing (12.13). The
majority of these patients had tachycardia refractory to type
1 antiarrhythmic drugs, but similar to reports (14.15) of
patients with drug-resistant atrial flutter or fibrillation, they
responded well to amiodarone therapy. A series of patients
with another variety of reentrant tachycardia, sinoatrial
reentrant tachycardia (16), had clinical and electrophysio-
logic characteristics very similar to those seen in our series.
Mechanisms. The observation that spontaneous or phar-
macologically induced AV block during ongoing tachycardia
failed to alter the cycle length or terminate the rhythm
suggests that the AV node was not a requisite limb of the
reentrant circuit. The configuration of the P waves and of the
atrial activation sequences observed during tachycardia was
distinct from that seen during sinus rhythm, thus excluding
the diagnosis of sinoatrial reentrant tachycardia (16). As
such, the location of these rhythms appears to be within the
atrium.
Reentry as the mechanism for the tachycardias in the
present series ofpatients may be inferred by their initiation
and termination by programmed stimulation (12,17-19). Al-
though criteria for entrainment were not demonstrated,
these are often dependent on pacing from a critical site
(20,21). In the present study, pacing was usually performed
from the high right atrium only. Also, the low amplitude of P
waves (as opposed to QRS complexes) during tachycardia
precluded reliable application of the "progressive fusion"
criterion during attempts to demonstrate transient entrain-
ment. However, termination of the tachycardias by rapid
lACC Vol. 15, No.6
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Figure 7. Patient 4. Surface electrocar-
diographic leads I and VI and intracar-
diac electrograms from the high right
atrium (HRA), the region of the His
bundle (HB) and the right ventricular
apex (RVA) during an episode of sus-
tained intraatrial reentrant tachycar-
dia. Panel A shows the atrial tachycar-
dia at baseline study, with an atrial
cycle length of 310 ms. Panel B, 18 s
after central venous injection of 7.6 mg
of adenosine, the patient developed
high grade atrioventricular (AV) block,
but no alteration of the atrial cycle
length was observed. Panel C, After
the adenosine effect had dissipated, 10
mg of verapamil was administered in-
travenously. Two minutes after injec-
tion, AV block had increased from 2: I
to 3: I, but atrial cycle length remained
unchanged at 310 ms.
v,
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Table 3. Long-Term Therapy in 19 Patients
·One patient developed amiodarone pulmonary toxicity and subsequently
underwent His bundle ablation. tone patient developed spontaneous high
grade atrioventricular (AV) block, and the second underwent catheter His
bundle ablation.
atrial pacing implies that transient concealed entrainment
likely did occur.
The response to programmed electrical stimulation does
not allow one to differentiate between rhythms due to
reentry and those caused by triggered activity (22). In vitro
(23,24) and clinical (25,26) studies suggest that triggered
activity is inhibited by verapamil or beta-adrenergic blocking
agents. Because the doses of these agents used in the present
study were moderate, strong conclusions cannot be made,
but the insensitivity of these rhythms to these agents in all
patients studied suggests that the arrhythmia mechanism
was unlikely to be due to triggered automaticity.
Quinidine (824 ± 197 mg/day)
Plus digoxin
Plus digoxinJatenolol
Disopyramide (600 mg/day) plus digoxin
Procainamide (3,000 mg/day)
Amiodarone (33 ± 150 mg/day)
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Conclusion. Intraatrial reentrant tachycardia is a fre-
quent cause of supraventricular tachycardia unresponsive to
conventional therapy. Its clinical presentation may be sub-
tle, and its mechanism is often misdiagnosed. It is usually
associated with underlying structural heart disease and other
ventricular and supraventricular arrhythmias. Concomitant
atrial flutter or fibrillation is seen in a majority of these
patients, suggesting that similar substrates are required for
propagation of these arrhythmias. The diagnosis of intra-
atrial reentrant tachycardia may be facilitated by production
of high grade AV block, but long-term therapy with agents
chiefly affecting AV node conduction alone is not effective.
Intraatrial reentrant tachycardia may be refractory to many
antiarrhythmic drugs, but may respond to long-term therapy
with low doses of oral amiodarone.
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